Advertisement

Medical Oncology

, 35:124 | Cite as

Broccoli extract improves chemotherapeutic drug efficacy against head–neck squamous cell carcinomas

  • Osama A. Elkashty
  • Ramy Ashry
  • Ghada Abu Elghanam
  • Hieu M. Pham
  • Xinyun Su
  • Camille Stegen
  • Simon D. TranEmail author
Original Paper

Abstract

The efficacy of cisplatin (CIS) and 5-fluorouracil (5-FU) against squamous cell carcinomas of the head and neck (SCCHN) remains restricted due to their severe toxic side effects on non-cancer (normal) tissues. Recently, the broccoli extract sulforaphane (SF) was successfully tested as a combination therapy to target cancer cells. However, the effect of lower doses of CIS or 5-FU combined with SF on SCCHN remained unknown. This study tested the chemotherapeutic efficacies of SF combined with much lower doses of CIS or 5-FU against SCCHN cells aiming to reduce cytotoxicity to normal cells. Titrations of SF standalone or in combination with CIS and 5-FU were tested on SCCHN human cell lines (SCC12 and SCC38) and non-cancerous human cells (fibroblasts, gingival, and salivary cells). Concentrations of SF tested were comparable to those found in the plasma following ingestion of fresh broccoli sprouts. The treatment effects on cell viability, proliferation, DNA damage, apoptosis, and gene expression were measured. SF reduced SCCHN cell viability in a time- and dose-dependent manner. SF-combined treatment increased the cytotoxic activity of CIS by twofolds and of 5-FU by tenfolds against SCCHN, with no effect on non-cancerous cells. SF-combined treatment inhibited SCCHN cell clonogenicity and post-treatment DNA repair. SF increased SCCHN apoptosis and this mechanism was due to a down-regulation of BCL2 and up-regulation of BAX, leading to an up-regulation of Caspase3. In conclusion, combining SF with low doses of CIS or 5-FU increased cytotoxicity against SCCHN cells, while having minimal effects on normal cells.

Keywords

Head and Neck cancer Carcinoma, squamous cell Sulforaphane Drug therapy Apoptosis DNA damage 

Notes

Acknowledgements

We would like to thank Murali Ramamoorthi, Andre Charbonneau, Mohamed Nur Abdallah, and Gulshan Sunavala-Dossabhoy for donating human SCC, fibroblasts, HGEPC, and NS-SV-AC, respectively. We also thank Younan Liu and Mohammed Bakkar for helpful discussion in setting up preliminary experiments.

Funding

This work was partly funded by Canadian Institutes of Health Research (CIHR Grant 119585), Natural Sciences and Engineering Research Council of Canada (NSERC Grant 05247), MJW Kim research fund, and the Ministry of Higher Education in Egypt (MOHE postgraduate studies funding).

Compliance with ethical standards

Conflict of interest

All authors declare that they have no conflict of interest.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Supplementary material

12032_2018_1186_MOESM1_ESM.docx (3.3 mb)
Supplementary material 1 (DOCX 3394 KB)

References

  1. 1.
    Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359-86.  https://doi.org/10.1002/ijc.29210.CrossRefPubMedGoogle Scholar
  2. 2.
    Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, Brenner H, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the Global Burden of Disease Study. JAMA Oncol. 2017;3(4):524–48.  https://doi.org/10.1001/jamaoncol.2016.5688.CrossRefPubMedGoogle Scholar
  3. 3.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.  https://doi.org/10.3322/caac.20107.CrossRefPubMedGoogle Scholar
  4. 4.
    Machiels JP, Lambrecht M, Hanin FX, Duprez T, Gregoire V, Schmitz S, et al. Advances in the management of squamous cell carcinoma of the head and neck. F1000prime Rep. 2014;6:44.  https://doi.org/10.12703/p6-44.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58(2):71–96.  https://doi.org/10.3322/ca.2007.0010.CrossRefPubMedGoogle Scholar
  6. 6.
    Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74–108.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 2003;22(47):7265–79.  https://doi.org/10.1038/sj.onc.1206933.CrossRefPubMedGoogle Scholar
  8. 8.
    Thomas SA, Grami Z, Mehta S, K Patel. Adverse effects of 5-fluorouracil: focus on rare side effects. Cancer Cell Microenviron. 2016; https://doi.org/10.14800/ccm.1266.CrossRefGoogle Scholar
  9. 9.
    Pabla N, Dong Z. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int. 2008;73(9):994–1007.  https://doi.org/10.1038/sj.ki.5002786.CrossRefPubMedGoogle Scholar
  10. 10.
    Park SB, Goldstein D, Krishnan AV, Lin CS, Friedlander ML, Cassidy J, et al. Chemotherapy-induced peripheral neurotoxicity: a critical analysis. CA Cancer J Clin. 2013;63(6):419–37.  https://doi.org/10.3322/caac.21204.CrossRefPubMedGoogle Scholar
  11. 11.
    De Jongh FE, van Veen RN, Veltman SJ, de Wit R, van der Burg ME, van den Bent MJ, et al. Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients. Br J Cancer. 2003;88(8):1199–206.  https://doi.org/10.1038/sj.bjc.6600884.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Xiao Z, Morris-Natschke SL, Lee KH. Strategies for the optimization of natural leads to anticancer drugs or drug candidates. Med Res Rev. 2016;36(1):32–91.  https://doi.org/10.1002/med.21377.CrossRefPubMedGoogle Scholar
  13. 13.
    Lenzi M, Fimognari C, Hrelia P. Sulforaphane as a promising molecule for fighting cancer. Cancer Treat Res. 2014;159:207–23.  https://doi.org/10.1007/978-3-642-38007-5_12.CrossRefPubMedGoogle Scholar
  14. 14.
    Singh SV, Srivastava SK, Choi S, Lew KL, Antosiewicz J, Xiao D, et al. Sulforaphane-induced cell death in human prostate cancer cells is initiated by reactive oxygen species. J Biol Chem. 2005;280(20):19911–24.  https://doi.org/10.1074/jbc.M412443200.CrossRefPubMedGoogle Scholar
  15. 15.
    Shen G, Khor TO, Hu R, Yu S, Nair S, Ho CT, et al. Chemoprevention of familial adenomatous polyposis by natural dietary compounds sulforaphane and dibenzoylmethane alone and in combination in ApcMin/+ mouse. Cancer Res. 2007;67(20):9937–44.  https://doi.org/10.1158/0008-5472.can-07-1112.CrossRefPubMedGoogle Scholar
  16. 16.
    Mi L, Wang X, Govind S, Hood BL, Veenstra TD, Conrads TP, et al. The role of protein binding in induction of apoptosis by phenethyl isothiocyanate and sulforaphane in human non-small lung cancer cells. Cancer Res. 2007;67(13):6409–16.  https://doi.org/10.1158/0008-5472.can-07-0340.CrossRefPubMedGoogle Scholar
  17. 17.
    Herman-Antosiewicz A, Xiao H, Lew KL, Singh SV. Induction of p21 protein protects against sulforaphane-induced mitotic arrest in LNCaP human prostate cancer cell line. Mol Cancer Ther. 2007;6(5):1673–81.  https://doi.org/10.1158/1535-7163.mct-06-0807.CrossRefPubMedGoogle Scholar
  18. 18.
    Lin LC, Yeh CT, Kuo CC, Lee CM, Yen GC, Wang LS, et al. Sulforaphane potentiates the efficacy of imatinib against chronic leukemia cancer stem cells through enhanced abrogation of Wnt/beta-catenin function. J Agric Food Chem. 2012;60(28):7031–9.  https://doi.org/10.1021/jf301981n.CrossRefPubMedGoogle Scholar
  19. 19.
    Kallifatidis G, Labsch S, Rausch V, Mattern J, Gladkich J, Moldenhauer G, et al. Sulforaphane increases drug-mediated cytotoxicity toward cancer stem-like cells of pancreas and prostate. Mol Ther. 2011;19(1):188–95.  https://doi.org/10.1038/mt.2010.216.CrossRefPubMedGoogle Scholar
  20. 20.
    Pham NA, Jacobberger JW, Schimmer AD, Cao P, Gronda M, Hedley DW. The dietary isothiocyanate sulforaphane targets pathways of apoptosis, cell cycle arrest, and oxidative stress in human pancreatic cancer cells and inhibits tumor growth in severe combined immunodeficient mice. Mol Cancer Ther. 2004;3(10):1239–48.PubMedGoogle Scholar
  21. 21.
    Schwarz S, Rotter N. Human salivary gland stem cells: isolation, propagation, and characterization. Methods Mol Biol (Clifton NJ). 2012;879:403–42.  https://doi.org/10.1007/978-1-61779-815-3_25.CrossRefGoogle Scholar
  22. 22.
    Abdallah MN, Abdollahi S, Laurenti M, Fang D, Tran SD, Cerruti M, et al. Scaffolds for epithelial tissue engineering customized in elastomeric molds. J Biomed Mater Res Part B. 2017.  https://doi.org/10.1002/jbm.b.33897.CrossRefGoogle Scholar
  23. 23.
    Expasy.org. 2017. http://web.expasy.org/cellosaurus/. Accessed 13 Sept 2017.
  24. 24.
    Brenner JC, Graham MP, Kumar B, Saunders LM, Kupfer R, Lyons RH, et al. Genotyping of 73 UM-SCC head and neck squamous cell carcinoma cell lines. Head Neck. 2010;32(4):417–26.  https://doi.org/10.1002/hed.21198.PubMedPubMedCentralCrossRefGoogle Scholar
  25. 25.
    Grenman R, Carey TE, McClatchey KD, Wagner JG, Pekkola-Heino K, Schwartz DR, et al. In vitro radiation resistance among cell lines established from patients with squamous cell carcinoma of the head and neck. Cancer. 1991;67(11):2741–7.CrossRefPubMedGoogle Scholar
  26. 26.
    Carey TE, Van Dyke DL, Worsham MJ. Nonrandom chromosome aberrations and clonal populations in head and neck cancer. Anticancer Res. 1993;13(6b):2561–7.PubMedGoogle Scholar
  27. 27.
    Nagel R, Martens-de Kemp SR, Buijze M, Jacobs G, Braakhuis BJ, Brakenhoff RH. Treatment response of HPV-positive and HPV-negative head and neck squamous cell carcinoma cell lines. Oral Oncol. 2013;49(6):560–6.  https://doi.org/10.1016/j.oraloncology.2013.03.446.CrossRefPubMedGoogle Scholar
  28. 28.
    Pekkola-Heino K, Joensuu H, Klemi P, Grenman R. Relation of DNA ploidy and proliferation rate to radiation sensitivity in squamous carcinoma cell lines. Arch Otolaryngol. 1994;120(7):750–4.CrossRefGoogle Scholar
  29. 29.
    Bradford CR, Zhu S, Ogawa H, Ogawa T, Ubell M, Narayan A, et al. P53 mutation correlates with cisplatin sensitivity in head and neck squamous cell carcinoma lines. Head Neck. 2003;25(8):654–61.  https://doi.org/10.1002/hed.10274.CrossRefPubMedGoogle Scholar
  30. 30.
    Martens-de Kemp SR, Dalm SU, Wijnolts FM, Brink A, Honeywell RJ, Peters GJ, et al. DNA-bound platinum is the major determinant of cisplatin sensitivity in head and neck squamous carcinoma cells. PLoS ONE. 2013;8(4):e61555.  https://doi.org/10.1371/journal.pone.0061555.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Wang L, Mosel AJ, Oakley GG, Peng A. Deficient DNA damage signaling leads to chemoresistance to cisplatin in oral cancer. Mol Cancer Ther. 2012;11(11):2401–9.  https://doi.org/10.1158/1535-7163.mct-12-0448.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Vermorken JB, Specenier P. Optimal treatment for recurrent/metastatic head and neck cancer. Ann Oncol. 2010;21(Suppl 7):vii252–61.  https://doi.org/10.1093/annonc/mdq453.PubMedCrossRefGoogle Scholar
  33. 33.
    Liu CM, Peng CY, Liao YW, Lu MY, Tsai ML, Yeh JC, et al. Sulforaphane targets cancer stemness and tumor initiating properties in oral squamous cell carcinomas via miR-200c induction. J Formos Med Assoc. 2017;116(1):41–8.  https://doi.org/10.1016/j.jfma.2016.01.004.CrossRefPubMedGoogle Scholar
  34. 34.
    Kim JH, Han Kwon K, Jung JY, Han HS, Hyun Shim J, Oh SJ, et al. Sulforaphane increases cyclin-dependent kinase inhibitor, p21 protein in human oral carcinoma cells and nude mouse animal model to induce G(2)/M cell cycle arrest. J Clin Biochem Nutr. 2010;46(1):60–7.  https://doi.org/10.3164/jcbn.09-65.PubMedCrossRefGoogle Scholar
  35. 35.
    Jee HG, Lee KE, Kim JB, Shin HK, Youn YK. Sulforaphane inhibits oral carcinoma cell migration and invasion in vitro. Phytother Res. 2011;25(11):1623–8.  https://doi.org/10.1002/ptr.3397.CrossRefPubMedGoogle Scholar
  36. 36.
    Suppipat K, Park CS, Shen Y, Zhu X, Lacorazza HD. Sulforaphane induces cell cycle arrest and apoptosis in acute lymphoblastic leukemia cells. PLoS ONE. 2012;7(12):e51251.  https://doi.org/10.1371/journal.pone.0051251.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Clarke JD, Hsu A, Riedl K, Bella D, Schwartz SJ, Stevens JF, et al. Bioavailability and inter-conversion of sulforaphane and erucin in human subjects consuming broccoli sprouts or broccoli supplement in a cross-over study design. Pharmacol Res. 2011;64(5):456–63.  https://doi.org/10.1016/j.phrs.2011.07.005.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Wang X, Li Y, Dai Y, Liu Q, Ning S, Liu J, et al. Sulforaphane improves chemotherapy efficacy by targeting cancer stem cell-like properties via the miR-124/IL-6R/STAT3 axis. Sci Rep. 2016;6:36796.  https://doi.org/10.1038/srep36796.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Al-Dimassi S, Abou-Antoun T, El-Sibai M. Cancer cell resistance mechanisms: a mini review. Clin Transl Oncol. 2014;16(6):511–6.  https://doi.org/10.1007/s12094-014-1162-1.CrossRefPubMedGoogle Scholar
  40. 40.
    Cho NP, Han HS, Leem DH, Choi IS, Jung JY, Kim HJ, et al. Sulforaphane enhances caspase-dependent apoptosis through inhibition of cyclooxygenase-2 expression in human oral squamous carcinoma cells and nude mouse xenograft model. Oral Oncol. 2009;45(8):654–60.  https://doi.org/10.1016/j.oraloncology.2008.07.003.CrossRefPubMedGoogle Scholar
  41. 41.
    Ferreira CG, Epping M, Kruyt FA, Giaccone G. Apoptosis: target of cancer therapy. Clin Cancer Res. 2002;8(7):2024–34.PubMedGoogle Scholar
  42. 42.
    Cryns V, Yuan J. Proteases to die for. Genes Dev. 1998;12(11):1551–70.CrossRefPubMedGoogle Scholar
  43. 43.
    Min K-j, Kwon TK. Anticancer effects and molecular mechanisms of epigallocatechin-3-gallate. Integr Med Res. 2014;3(1):16–24.  https://doi.org/10.1016/j.imr.2013.12.001.CrossRefPubMedGoogle Scholar
  44. 44.
    Devi JR, Thangam EB. Mechanisms of anticancer activity of sulforaphane from Brassica oleracea in HEp-2 human epithelial carcinoma cell line. Asian Pac J Cancer Prevent. 2012;13(5):2095–100.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.McGill Craniofacial Tissue Engineering and Stem Cells Laboratory, Faculty of DentistryMcGill UniversityMontrealCanada
  2. 2.Oral Pathology Department, Faculty of DentistryMansoura UniversityMansouraEgypt
  3. 3.Faculty of MedicineUniversity of JordanAmmanJordan
  4. 4.College of StomatologyGuangxi Medical UniversityNanningChina
  5. 5.Department of Microbiology and ImmunologyMcGill UniversityMontrealCanada
  6. 6.Microbiome and Disease Tolerance CenterMcGill UniversityMontrealCanada

Personalised recommendations